GlaxoSmithKline, Genmab Get Conditional Approval for Arzerra in EU

GlaxoSmithKline and Denmark’s Genmab A/S said that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP gave a positive opinion for conditional approval for its Arzerra, a treatment for refractory chronic lymphocytic leukaemia.
RTTNews